of a new six-month 45-mg formulation of Lupron® Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer. Palliative treatment helps to ...

June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron Depot ...

The FDA is reviewing Abbott’s supplemental New Drug Application for a new six-month 45-mg formulation of Lupron Depot (leuprolide acetate for depot suspension) for the palliative treatment of ...

This open-label study evaluated the efficacy and safety of a new leuprolide acetate 45 mg 6-month depot formulation in 151 men with prostate cancer who received 2 intramuscular injections ...

Leuprolide acetate 45mg; depot susp for IM inj; preservative-free. Give as single IM inj into gluteal area, anterior thigh or deltoid; rotate inj sites. 45mg once every 6 months (24 weeks).

Cipla is introducing leuprolide acetate injection depot, 22.5 mg, which is the generic of AbbVie’s Lupron Depot. It is indicated for palliative treatment of advanced prostate cancer. Leuprolide ...

Leuprolide acetate injection depot contains 22.5 mg of leuprolide acetate for 3-month administration given as a single dose injection. It is supplied as lyophilized microspheres in a single dose vial ...

Cipla has launched Leuprolide Acetate Injection Depot ... 505b2 regulatory pathway Leuprolide Acetate Injection Depot contains 225 mg of leuprolide acetate for 3-month administration given as ...

The product was approved by the United States Food and Drug Administration (USFDA) Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a ...